本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

MIRXES-B

30.000
+6.70028.76%
成交量:917.87万
成交额:2.75亿
市值:82.90亿
市盈率:- -
高:31.950
开:29.000
低:29.000
收:23.300
数据加载中...

公司资料

公司名字:
MIRXES-B
交易所:
SEHK
成立时间:
2014
员工人数:
352
公司地址:
2 Tukang Innovation Grove,#09-02 JTC MedTech Hub,Singapore,Singapore
邮编:
618305
电话:
传真:
- -
简介:
MiRXES Holding Company Limited is a micro ribonucleic acid (miRNA) technology company specializing in early cancer detection and precision medicine. It develops and commercializes accurate, non-invasive, and affordable blood-based miRNA test kit products for the early detection of cancer and other diseases. Its segments include Infectious diseases and Early detection and precision multi-omics. Its solutions include cancer screening; clinical sequencing; cancer treatment selection, and infectious diseases. Its core product (namely, GASTROClear), two other commercialized products (namely, LUNGClear and Fortitude), and six product candidates at pre-clinical stage. GASTROClear is a blood-based miRNA detection panel consisting of 12 miRNA biomarkers for gastric cancer screening. LUNGClear, its lung cancer screening product candidate, is a detection panel consisting of miRNA biomarkers discovered and verified in multi-center studies. It offers complete COVID-19 testing solutions.